BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 23225424)

  • 1. Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
    Nakajima Y; Takagi H; Kakizaki S; Horiguchi N; Sato K; Sunaga N; Mori M
    Anticancer Res; 2012 Dec; 32(12):5251-62. PubMed ID: 23225424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response.
    Judde JG; Rebucci M; Vogt N; de Cremoux P; Livartowski A; Chapelier A; Tran-Perennou C; Boye K; Defrance R; Poupon MF; Bras-Gonçalves RA
    Int J Cancer; 2007 Apr; 120(7):1579-90. PubMed ID: 17205515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo.
    Yang SH; Lin HY; Chang VH; Chen CC; Liu YR; Wang J; Zhang K; Jiang X; Yen Y
    Oncotarget; 2015 Sep; 6(27):23857-73. PubMed ID: 26160843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration.
    Hidalgo M; Amador ML; Jimeno A; Mezzadra H; Patel P; Chan A; Nielsen ME; Maitra A; Altiok S
    Mol Cancer Ther; 2006 Jul; 5(7):1895-903. PubMed ID: 16891476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases.
    Matsumoto K; Nagahara T; Okano J; Murawaki Y
    Oncol Rep; 2008 Oct; 20(4):863-72. PubMed ID: 18813828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
    Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
    PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
    Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
    Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
    Zhang Z; Oyesanya RA; Campbell DJ; Almenara JA; Dewitt JL; Sirica AE
    Hepatology; 2010 Sep; 52(3):975-86. PubMed ID: 20607690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel strategy of EGFR‑TKI combined chemotherapy in the treatment of human lung cancer with EGFR‑sensitive mutation.
    Zhang L; Qi Y; Xing K; Qian S; Zhang P; Wu X
    Oncol Rep; 2018 Aug; 40(2):1046-1054. PubMed ID: 29917169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
    Stabile LP; Lyker JS; Gubish CT; Zhang W; Grandis JR; Siegfried JM
    Cancer Res; 2005 Feb; 65(4):1459-70. PubMed ID: 15735034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
    Iwai T; Moriya Y; Shirane M; Fujimoto-Ouchi K; Mori K
    Oncol Rep; 2012 Apr; 27(4):923-8. PubMed ID: 22209766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.
    Zhu H; Cheng H; Ren Y; Liu ZG; Zhang YF; De Luo B
    Mol Biol Rep; 2012 Apr; 39(4):4971-9. PubMed ID: 22160570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
    Naumov GN; Nilsson MB; Cascone T; Briggs A; Straume O; Akslen LA; Lifshits E; Byers LA; Xu L; Wu HK; Jänne P; Kobayashi S; Halmos B; Tenen D; Tang XM; Engelman J; Yeap B; Folkman J; Johnson BE; Heymach JV
    Clin Cancer Res; 2009 May; 15(10):3484-94. PubMed ID: 19447865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells.
    Okita R; Wolf D; Yasuda K; Maeda A; Yukawa T; Saisho S; Shimizu K; Yamaguchi Y; Oka M; Nakayama E; Lundqvist A; Kiessling R; Seliger B; Nakata M
    PLoS One; 2015; 10(10):e0139809. PubMed ID: 26439264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinoma.
    Cho S; Lee TS; Song IH; Kim AR; Lee YJ; Kim H; Hwang H; Jeong MS; Kang SG; Hong HJ
    PLoS One; 2017; 12(2):e0170078. PubMed ID: 28166242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmalemma vesicle-associated protein promotes angiogenesis in cholangiocarcinoma via the DKK1/CKAP4/PI3K signaling pathway.
    Wang Y; Yu H; Xie X; Deng T; Ye L; Wu L; Ding X; Yang Z; Zhu Q; Li J; Zheng Y; Yu Z; Chen G
    Oncogene; 2021 Jun; 40(25):4324-4337. PubMed ID: 34079085
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Samankul A; Senawong G; Utaiwat S; Prompipak J; Woranam K; Phaosiri C; Sripa B; Senawong T
    Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512080
    [No Abstract]   [Full Text] [Related]  

  • 19. Enhancing the Therapeutic Efficacy of Gefitinib in Human Non-Small-Cell Lung Cancer through Drug Combination.
    Zhang M; Cai H; Du Y; Wang Y; Gong J; Xu J; Liu X
    Mol Pharm; 2021 Mar; 18(3):1397-1407. PubMed ID: 33471533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hedgehog pathway as a potential treatment target in human cholangiocarcinoma.
    Riedlinger D; Bahra M; Boas-Knoop S; Lippert S; Bradtmöller M; Guse K; Seehofer D; Bova R; Sauer IM; Neuhaus P; Koch A; Kamphues C
    J Hepatobiliary Pancreat Sci; 2014 Aug; 21(8):607-15. PubMed ID: 24733827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.